08:00-08:05 | 1: Welcome & Introduction Marc Ferrante, Leuven, Belgium |
||
08:05-09:45 | Session 1: Evolving endpoint in IBD clinical trials Javier Gisbert, Madrid, Spain |
||
08:05-08:25 | 2: Patient Reported Outcomes Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France |
||
08:25-08:45 | 3: Defining endoscopic endpoins Krisztina Gecse, Amsterdam, The Netherlands |
||
08:45-09:05 | 4: Cross-sectional imaging Andrea Laghi, Latina, Italy |
||
09:05-09:25 | 5: Histologic remission Roger Feakins, London, United Kingdom |
||
09:25-09:45 | 6: How endpoints can influence trial design? Walter Reinisch, Vienna, Austria |
||
09:45-10:15 | Coffee break | ||
10:15-11:30 | Session 2: Comparative effectiveness research (CER) John Mansfield, Newcastle upon Tyne, United Kingdom |
||
10:15-10:30 | 7: General principles Jean-Frédéric Colombel, New York, United States |
||
10:30-10:50 | 8: What is the value of retrospective CER? Pieter Hindryckx, Ghent, Belgium |
||
10:50-11:10 | 9: Head-to-head trials Simon Travis, Oxford, United Kingdom |
||
11:10-11:30 | 10: Setting priorities for IBD (discussion) Jean-Frédéric Colombel, New York, United States Pieter Hindryckx, Ghent, Belgium Simon Travis, Oxford, United Kingdom John Mansfield, Newcastle upon Tyne, United Kingdom Elmer Schabel, Bonn, Germany |
||
11:30-11:40 | 11: Summary & Closing remarks Marc Ferrante, Leuven, Belgium |